Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis.

ABSTRACT:

Objective

biologics have significantly advanced the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). However, real-world data regarding the risks of pulmonary fungal infections (PFI) associated with different biologics are limited. Our study aimed to explore PFI incidence among approved biologics, drawing on sources of real-world evidence.

Methods

We conducted a disproportionality analysis to evaluate the association between biologics and PFI using data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) (2004-2024). We analyzed clinical features, co-occurring adverse events (AEs), time-to-onset (TTO).

Results

Our analysis included 3,695 patients who developed PFI following treatment with biologics. The study compris

SUBMITTER: Li J 

PROVIDER: S-EPMC12580261 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature